SIRT1 Activation Disrupts Maintenance of Myelodysplastic Syndrome Stem and Progenitor Cells by Restoring TET2 Function

Jie Sun, Xin He, Yinghui Zhu, Zonghui Ding, Haojie Dong, Yimei Feng, Juan Du, Hanying Wang, Xiwei Wu, Lei Zhang, Xiaochun Yu, Allen Lin, Tinisha McDonald, Dandan Zhao, Herman Wu, Wei Kai Hua, Bin Zhang, Lifeng Feng, Kaoru Tohyama, Ravi BhatiaPhilipp Oberdoerffer, Yang Jo Chung, Peter D. Aplan, Jacqueline Boultwood, Andrea Pellagatti, Samer Khaled, Marcin Kortylewski, Flavia Pichiorri, Ya Huei Kuo, Nadia Carlesso, Guido Marcucci, Hongchuan Jin, Ling Li

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Myelodysplastic syndrome (MDS), a largely incurable hematological malignancy, is derived from aberrant clonal hematopoietic stem/progenitor cells (HSPCs) that persist after conventional therapies. Defining the mechanisms underlying MDS HSPC maintenance is critical for developing MDS therapy. The deacetylase SIRT1 regulates stem cell proliferation, survival, and self-renewal by deacetylating downstream proteins. Here we show that SIRT1 protein levels were downregulated in MDS HSPCs. Genetic or pharmacological activation of SIRT1 inhibited MDS HSPC functions, whereas SIRT1 deficiency enhanced MDS HSPC self-renewal. Mechanistically, the inhibitory effects of SIRT1 were dependent on TET2, a safeguard against HSPC transformation. SIRT1 deacetylated TET2 at conserved lysine residues in its catalytic domain, enhancing TET2 activity. Our genome-wide analysis identified cancer-related genes regulated by the SIRT1/TET2 axis. SIRT1 activation also inhibited functions of MDS HSPCs from patients with TET2 heterozygous mutations. Altogether, our results indicate that restoring TET2 function through SIRT1 activation represents a promising means to target MDS HSPCs. An improved understanding of the mechanisms regulating myelodysplastic syndrome (MDS) hematopoietic stem/progenitor cell (HSPC) growth and self-renewal is critical for developing MDS therapy. Sun et al. report that SIRT1 deficiency-induced TET2 hyperacetylation promotes MDS HSPC function and provides an approach to target MDS HSPCs by activating SIRT1 deacetylase.

Original languageEnglish (US)
Pages (from-to)355-369.e9
JournalCell Stem Cell
Volume23
Issue number3
DOIs
StatePublished - Sep 6 2018
Externally publishedYes

Fingerprint

Myelodysplastic Syndromes
Hematopoietic Stem Cells
Stem Cells
Maintenance

Keywords

  • acetylation
  • HSPCs
  • myelodysplastic syndrome
  • SIRT1
  • SRT1720
  • TET2

ASJC Scopus subject areas

  • Molecular Medicine
  • Genetics
  • Cell Biology

Cite this

SIRT1 Activation Disrupts Maintenance of Myelodysplastic Syndrome Stem and Progenitor Cells by Restoring TET2 Function. / Sun, Jie; He, Xin; Zhu, Yinghui; Ding, Zonghui; Dong, Haojie; Feng, Yimei; Du, Juan; Wang, Hanying; Wu, Xiwei; Zhang, Lei; Yu, Xiaochun; Lin, Allen; McDonald, Tinisha; Zhao, Dandan; Wu, Herman; Hua, Wei Kai; Zhang, Bin; Feng, Lifeng; Tohyama, Kaoru; Bhatia, Ravi; Oberdoerffer, Philipp; Chung, Yang Jo; Aplan, Peter D.; Boultwood, Jacqueline; Pellagatti, Andrea; Khaled, Samer; Kortylewski, Marcin; Pichiorri, Flavia; Kuo, Ya Huei; Carlesso, Nadia; Marcucci, Guido; Jin, Hongchuan; Li, Ling.

In: Cell Stem Cell, Vol. 23, No. 3, 06.09.2018, p. 355-369.e9.

Research output: Contribution to journalArticle

Sun, J, He, X, Zhu, Y, Ding, Z, Dong, H, Feng, Y, Du, J, Wang, H, Wu, X, Zhang, L, Yu, X, Lin, A, McDonald, T, Zhao, D, Wu, H, Hua, WK, Zhang, B, Feng, L, Tohyama, K, Bhatia, R, Oberdoerffer, P, Chung, YJ, Aplan, PD, Boultwood, J, Pellagatti, A, Khaled, S, Kortylewski, M, Pichiorri, F, Kuo, YH, Carlesso, N, Marcucci, G, Jin, H & Li, L 2018, 'SIRT1 Activation Disrupts Maintenance of Myelodysplastic Syndrome Stem and Progenitor Cells by Restoring TET2 Function', Cell Stem Cell, vol. 23, no. 3, pp. 355-369.e9. https://doi.org/10.1016/j.stem.2018.07.018
Sun, Jie ; He, Xin ; Zhu, Yinghui ; Ding, Zonghui ; Dong, Haojie ; Feng, Yimei ; Du, Juan ; Wang, Hanying ; Wu, Xiwei ; Zhang, Lei ; Yu, Xiaochun ; Lin, Allen ; McDonald, Tinisha ; Zhao, Dandan ; Wu, Herman ; Hua, Wei Kai ; Zhang, Bin ; Feng, Lifeng ; Tohyama, Kaoru ; Bhatia, Ravi ; Oberdoerffer, Philipp ; Chung, Yang Jo ; Aplan, Peter D. ; Boultwood, Jacqueline ; Pellagatti, Andrea ; Khaled, Samer ; Kortylewski, Marcin ; Pichiorri, Flavia ; Kuo, Ya Huei ; Carlesso, Nadia ; Marcucci, Guido ; Jin, Hongchuan ; Li, Ling. / SIRT1 Activation Disrupts Maintenance of Myelodysplastic Syndrome Stem and Progenitor Cells by Restoring TET2 Function. In: Cell Stem Cell. 2018 ; Vol. 23, No. 3. pp. 355-369.e9.
@article{779bf92f19a14eca84e16fd9c6151bc1,
title = "SIRT1 Activation Disrupts Maintenance of Myelodysplastic Syndrome Stem and Progenitor Cells by Restoring TET2 Function",
abstract = "Myelodysplastic syndrome (MDS), a largely incurable hematological malignancy, is derived from aberrant clonal hematopoietic stem/progenitor cells (HSPCs) that persist after conventional therapies. Defining the mechanisms underlying MDS HSPC maintenance is critical for developing MDS therapy. The deacetylase SIRT1 regulates stem cell proliferation, survival, and self-renewal by deacetylating downstream proteins. Here we show that SIRT1 protein levels were downregulated in MDS HSPCs. Genetic or pharmacological activation of SIRT1 inhibited MDS HSPC functions, whereas SIRT1 deficiency enhanced MDS HSPC self-renewal. Mechanistically, the inhibitory effects of SIRT1 were dependent on TET2, a safeguard against HSPC transformation. SIRT1 deacetylated TET2 at conserved lysine residues in its catalytic domain, enhancing TET2 activity. Our genome-wide analysis identified cancer-related genes regulated by the SIRT1/TET2 axis. SIRT1 activation also inhibited functions of MDS HSPCs from patients with TET2 heterozygous mutations. Altogether, our results indicate that restoring TET2 function through SIRT1 activation represents a promising means to target MDS HSPCs. An improved understanding of the mechanisms regulating myelodysplastic syndrome (MDS) hematopoietic stem/progenitor cell (HSPC) growth and self-renewal is critical for developing MDS therapy. Sun et al. report that SIRT1 deficiency-induced TET2 hyperacetylation promotes MDS HSPC function and provides an approach to target MDS HSPCs by activating SIRT1 deacetylase.",
keywords = "acetylation, HSPCs, myelodysplastic syndrome, SIRT1, SRT1720, TET2",
author = "Jie Sun and Xin He and Yinghui Zhu and Zonghui Ding and Haojie Dong and Yimei Feng and Juan Du and Hanying Wang and Xiwei Wu and Lei Zhang and Xiaochun Yu and Allen Lin and Tinisha McDonald and Dandan Zhao and Herman Wu and Hua, {Wei Kai} and Bin Zhang and Lifeng Feng and Kaoru Tohyama and Ravi Bhatia and Philipp Oberdoerffer and Chung, {Yang Jo} and Aplan, {Peter D.} and Jacqueline Boultwood and Andrea Pellagatti and Samer Khaled and Marcin Kortylewski and Flavia Pichiorri and Kuo, {Ya Huei} and Nadia Carlesso and Guido Marcucci and Hongchuan Jin and Ling Li",
year = "2018",
month = "9",
day = "6",
doi = "10.1016/j.stem.2018.07.018",
language = "English (US)",
volume = "23",
pages = "355--369.e9",
journal = "Cell Stem Cell",
issn = "1934-5909",
publisher = "Cell Press",
number = "3",

}

TY - JOUR

T1 - SIRT1 Activation Disrupts Maintenance of Myelodysplastic Syndrome Stem and Progenitor Cells by Restoring TET2 Function

AU - Sun, Jie

AU - He, Xin

AU - Zhu, Yinghui

AU - Ding, Zonghui

AU - Dong, Haojie

AU - Feng, Yimei

AU - Du, Juan

AU - Wang, Hanying

AU - Wu, Xiwei

AU - Zhang, Lei

AU - Yu, Xiaochun

AU - Lin, Allen

AU - McDonald, Tinisha

AU - Zhao, Dandan

AU - Wu, Herman

AU - Hua, Wei Kai

AU - Zhang, Bin

AU - Feng, Lifeng

AU - Tohyama, Kaoru

AU - Bhatia, Ravi

AU - Oberdoerffer, Philipp

AU - Chung, Yang Jo

AU - Aplan, Peter D.

AU - Boultwood, Jacqueline

AU - Pellagatti, Andrea

AU - Khaled, Samer

AU - Kortylewski, Marcin

AU - Pichiorri, Flavia

AU - Kuo, Ya Huei

AU - Carlesso, Nadia

AU - Marcucci, Guido

AU - Jin, Hongchuan

AU - Li, Ling

PY - 2018/9/6

Y1 - 2018/9/6

N2 - Myelodysplastic syndrome (MDS), a largely incurable hematological malignancy, is derived from aberrant clonal hematopoietic stem/progenitor cells (HSPCs) that persist after conventional therapies. Defining the mechanisms underlying MDS HSPC maintenance is critical for developing MDS therapy. The deacetylase SIRT1 regulates stem cell proliferation, survival, and self-renewal by deacetylating downstream proteins. Here we show that SIRT1 protein levels were downregulated in MDS HSPCs. Genetic or pharmacological activation of SIRT1 inhibited MDS HSPC functions, whereas SIRT1 deficiency enhanced MDS HSPC self-renewal. Mechanistically, the inhibitory effects of SIRT1 were dependent on TET2, a safeguard against HSPC transformation. SIRT1 deacetylated TET2 at conserved lysine residues in its catalytic domain, enhancing TET2 activity. Our genome-wide analysis identified cancer-related genes regulated by the SIRT1/TET2 axis. SIRT1 activation also inhibited functions of MDS HSPCs from patients with TET2 heterozygous mutations. Altogether, our results indicate that restoring TET2 function through SIRT1 activation represents a promising means to target MDS HSPCs. An improved understanding of the mechanisms regulating myelodysplastic syndrome (MDS) hematopoietic stem/progenitor cell (HSPC) growth and self-renewal is critical for developing MDS therapy. Sun et al. report that SIRT1 deficiency-induced TET2 hyperacetylation promotes MDS HSPC function and provides an approach to target MDS HSPCs by activating SIRT1 deacetylase.

AB - Myelodysplastic syndrome (MDS), a largely incurable hematological malignancy, is derived from aberrant clonal hematopoietic stem/progenitor cells (HSPCs) that persist after conventional therapies. Defining the mechanisms underlying MDS HSPC maintenance is critical for developing MDS therapy. The deacetylase SIRT1 regulates stem cell proliferation, survival, and self-renewal by deacetylating downstream proteins. Here we show that SIRT1 protein levels were downregulated in MDS HSPCs. Genetic or pharmacological activation of SIRT1 inhibited MDS HSPC functions, whereas SIRT1 deficiency enhanced MDS HSPC self-renewal. Mechanistically, the inhibitory effects of SIRT1 were dependent on TET2, a safeguard against HSPC transformation. SIRT1 deacetylated TET2 at conserved lysine residues in its catalytic domain, enhancing TET2 activity. Our genome-wide analysis identified cancer-related genes regulated by the SIRT1/TET2 axis. SIRT1 activation also inhibited functions of MDS HSPCs from patients with TET2 heterozygous mutations. Altogether, our results indicate that restoring TET2 function through SIRT1 activation represents a promising means to target MDS HSPCs. An improved understanding of the mechanisms regulating myelodysplastic syndrome (MDS) hematopoietic stem/progenitor cell (HSPC) growth and self-renewal is critical for developing MDS therapy. Sun et al. report that SIRT1 deficiency-induced TET2 hyperacetylation promotes MDS HSPC function and provides an approach to target MDS HSPCs by activating SIRT1 deacetylase.

KW - acetylation

KW - HSPCs

KW - myelodysplastic syndrome

KW - SIRT1

KW - SRT1720

KW - TET2

UR - http://www.scopus.com/inward/record.url?scp=85052668847&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85052668847&partnerID=8YFLogxK

U2 - 10.1016/j.stem.2018.07.018

DO - 10.1016/j.stem.2018.07.018

M3 - Article

C2 - 30146412

AN - SCOPUS:85052668847

VL - 23

SP - 355-369.e9

JO - Cell Stem Cell

JF - Cell Stem Cell

SN - 1934-5909

IS - 3

ER -